Oculis Holding AG (NASDAQ:OCS) Receives Average Rating of “Moderate Buy” from Analysts

Oculis Holding AG (NASDAQ:OCS) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $41.50.

OCS has been the topic of several research reports. Stifel Nicolaus boosted their price target on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. Finally, Bank of America reduced their target price on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th.

Oculis Trading Down 0.5%

Shares of OCS stock opened at $28.35 on Thursday. The firm has a market capitalization of $1.48 billion, a P/E ratio of -11.25 and a beta of 0.27. Oculis has a 1 year low of $14.00 and a 1 year high of $29.36. The firm’s fifty day simple moving average is $22.99 and its 200 day simple moving average is $20.17. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, sell-side analysts predict that Oculis will post -2.09 EPS for the current year.

Institutional Trading of Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Bank of America Corp DE lifted its stake in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC bought a new position in shares of Oculis during the 4th quarter worth approximately $80,000. Geode Capital Management LLC boosted its stake in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA grew its position in Oculis by 10.6% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after acquiring an additional 10,300 shares during the period. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.